Tolerability and Satisfaction With Evie
- Conditions
- Infertility
- Interventions
- Device: Evie Slow-release Insemination DeviceOther: Traditional Intrauterine Insemination
- Registration Number
- NCT01969812
- Lead Sponsor
- Wake Forest University Health Sciences
- Brief Summary
The purpose of this study is to determine patient satisfaction and tolerability of the Evie® slow-release insemination device for US population. Additionally, to assess cramping with the device and to determine pregnancy rates using the slow insemination device compared to standard IUI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 22
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Evie Slow-Release Insemination Device Evie Slow-release Insemination Device Preliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter. Traditional Intrauterine Insemination Traditional Intrauterine Insemination Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
- Primary Outcome Measures
Name Time Method Patient Tolerability and Satisfaction SF36 1 month The primary outcome variable will be patient tolerability and satisfaction, based on a standardized SF-36 survey.
Total score 0-100 with higher score denoting better outcomes
- Secondary Outcome Measures
Name Time Method Cramping 1 month Cramping assessment based on a Numerical Rating Scale 0 to 10. Higher score denotes worse cramping.
Pregnancy Rates 3 months Pregnancy rates based on blood and urine beta-HCG.
Trial Locations
- Locations (1)
Women's Institute at Carolinas Medical Center
🇺🇸Charlotte, North Carolina, United States